Revolutionary innovations are underway to industrialize cell and gene therapies
Jun
13
2024
On demand

Revolutionary innovations are underway to industrialize cell and gene therapies

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Revolutionary innovations are underway to industrialize cell and gene therapies

An exploration of the challenges in the cell and gene therapy space today is necessary due to the unique complexity of CGTs compared to other biologic modalities.

In this discussion, we will explore the complex landscape of process development and analytical development, while reviewing key focus areas based on lessons learned across our experiences. The discussion will be framed around where the market is headed and how breakthroughs will make for a bright future.

  • The critical importance of considering process development early on
  • The benefits of reducing manual and open processing
  • Standardized approaches and processes for scalable manufacturing in addition to standardized analytics and consumables wherever possible
  • The importance of people and quality systems
Mark Santos
Mark Santos
Global Head of Commercial Development & Marketing, Cell & Gene Technologies at Lonza

Mark is the commercial and marketing lead for Lonza’s CGT Business unit. His responsibilities include promoting & designing Lonza’s CGT offerings and capabilities. This includes strategic relationships, investment prioritization and offerings within Lonza’s CGT business to result in high value partnerships.

Mark has 15+ years of experience in the Biopharmaceutical space. He currently lives in the United States. Previously he was in Switzerland to help build the Strategic and Innovation roadmap for Lonza’s Bioconjugate business unit. He has led the development and delivery of multiple large investment projects across mammalian, bioconjugate and vaccine technologies. He worked for PwC Pharma R&D Ops to help transform business & operational planning for large pharmaceutical organizations. His career started in mammalian and microbial manufacturing.

Mark has a Masters in Business Administration & a Microbial degree from the University of New Hampshire.

SPEAKERS

Mark Santos
Mark Santos
Global Head of Commercial Development & Marketing, Cell & Gene Technologies at Lonza

You might also like

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.
5 June
Watch
Mastering the journey from initial method transfer to successful lot release for cell & gene therapies

Mastering the journey from initial method transfer to successful lot release for cell & gene therapies

A Chang, H Malicki, J Cheung et al.
6 June
Watch
Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic

Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic

Tey Irrazabal
1 February
Watch
Considerations to optimize and act upon long-term follow-up studies for cell and gene therapies

Considerations to optimize and act upon long-term follow-up studies for cell and gene therapies

K Wonnacott, L Pelloso, D Takefman et al.
11 April
Watch